Education only. EverLife Capital publishes general, impersonal educational research, not personalized investment or medical advice. Nothing here is a recommendation to buy, sell or hold any security. Biotech investments can lose their entire value.
Welcome back. Today I'm excited to share one of the most interesting targets in aging: jumping genes. We'll look at what they could mean for your healthspan and lifespan, what's actually been shown, and what the companies working on them still need to prove.
Most of the companies I found worldwide are private, and private companies can go public one day. So is this something to take seriously now, or something to wait on? Let's get into it.
What Is A Jumping Gene?
Our DNA carries some strange passengers.
Ancient viruses. Over the course of evolution, viruses called endogenous retroviruses (HERVs) left pieces of themselves in our DNA, and we've passed them down ever since.[1]
LINE-1. The most common jumping gene is a different kind of passenger: a stretch of mobile DNA that can copy itself.[2]
LINE-1 doesn't really jump. It makes a copy of itself and pastes the copy into a new spot in your DNA.
Over millions of years, that may have helped us evolve. But within one lifetime, these genes wake up as we age, and that can contribute to decline.[2][3]
Here's how I think of it. You're baking a cake, and someone comes in and adds ingredients you didn't expect. The cake could come out better, or it could come out worse. Most of us would rather have the cake the way it was meant to be and skip the risk.
Is This An Upstream Driver Of Aging?
I believe it could be, and it overlaps with many other drivers.
In my last issue, I shared the framework: find the best-in-class companies for each hallmark of aging, and go upstream where we can. The NLRP3 inflammasome is one upstream driver behind many diseases of aging. Senescent (zombie) cells are another.
Jumping genes connect to both. A copy that lands in the wrong place can disrupt a gene we need. And the copies look like a virus to our cells, so the cell sounds an alarm and releases inflammatory signals.[2][4] Over time, that feeds the constant inflammation linked to aging.
These deals were for drugs that calm a different inflammation alarm, NLRP3, not for jumping-gene drugs. They show the context, not what a jumping-gene program is worth.
Eli Lilly completed its purchase of Ventyx Biosciences in March 2026, at an announced equity value of about $1.2 billion. The deal covered a pipeline, not one drug.[5]
Roche paid €376 million at closing for Inflazome in 2020, plus possible later payments.[6]
Novartis bought IFM Tre in 2019 for $310 million upfront, with up to $1.575 billion total.[7]
No one can predict whether jumping-gene drugs will draw deals like these. But pharma has shown it will pay for early drugs that calm age-linked inflammation.
What's Being Tested Right Now?
1. Block the copying enzyme. Jumping genes need one enzyme to copy themselves.
In mice: Researchers engineered mice without a protective gene called SIRT6. In these mice, jumping genes run wild and the mice age prematurely. Blocking the copying enzyme partly rescued them: they lived about twice as long, though still far short of normal mice.[3] That alone suggests boosting SIRT6 could help too, and researchers are studying it.[8]
In people: Enzyme blockers have been tested in people with brain and nerve diseases, including one large ALS trial. They haven't been tested for lifespan or healthspan in healthy people. A trial in healthy older adults is planned.[9]
2. Remove zombie cells. I find this one interesting because it shows how these targets overlap. Some zombie cells, the old cells that should have stopped working, show higher jumping-gene activity.[2][12] Maybe that's part of how they became zombie cells. Whether clearing them would lower jumping-gene activity across the body is still a hypothesis, but it's one worth testing.
3. Strengthen the DNA's own guards. Elephants have at least 20 copies of a gene called p53, compared with our one, and they rarely die of cancer.[10] In flies and fish, p53 helps keep jumping genes in check.[11] That points to other ways of keeping our DNA stable.
So, Is There A Business Case Yet?
You may be wondering whether these companies offer real upside, with some pharma interest.
I'll share my evaluation in the members area. Millions of dollars have already gone into these companies, and I scratched my head when I saw it.
In the members area, I'll share:
My 25-gate view on these companies, and why they landed where they did.
What I'm watching for, and what evidence would change my view.
The key study being planned, what it could reveal, and how to read the results when they come out.
That way you can build your own watch list too.
I'll see you in the members area.
Eric
Sources
1. Human endogenous retroviruses in the human genome. PubMed ID 11591322.
2. De Cecco M et al. "L1 drives IFN in senescent cells and promotes age-associated inflammation." Nature. 2019;566:73-78. PubMed ID 30728521.
3. Simon M et al. "LINE1 derepression in aged wild-type and SIRT6-deficient mice drives inflammation." Cell Metabolism. 2019. PMC6449196.
4. Lifespan.io. "Why We Age: Chronic Inflammation."
5. Eli Lilly and Company. SEC filing on completion of the Ventyx Biosciences acquisition, March 2026.
6. Roche. Finance Report 2020, Inflazome acquisition note.
7. Novartis. "Novartis to acquire IFM Tre." Apr 1, 2019.
8. Roichman A et al. "Restoration of energy homeostasis by SIRT6 extends healthy lifespan." Nature Communications. 2021.
9. University of Rochester. "ARPA-H funding for retrotransposons and aging." Feb 24, 2026.
10. Abegglen LM et al. JAMA. 2015;314(17):1850-1860.
11. Wylie A et al. "p53 genes function to restrain mobile elements." Genes & Development. 2016;30(1):64-77.
12. LINE-1 activity differences by cell type. Nucleic Acids Research. 2026 (doi 10.1093/nar/gkag522).
EverLife Capital publishes general educational research, not personalized investment or medical advice. Past acquisitions don't predict future ones. Animal results may not apply to people. I hold personal equity in Repair Biotechnologies and Yuva Biosciences, neither discussed here. No company covered paid for coverage. EverLife Capital is published by Consult US, LLC.
